Department of Medicine, Division of Gastroenterology University of Toronto. morris.sherman@uhn.on.ca.

Abstract

It has been difficult to prove that hepatitis B treatment reduces the incidence of hepatocellular carcinoma. Most previous studies have been retrospective without adequate controls. In this issue of Hepatology Hosaka et al present data on a large cohort, propensity matched for HCC risk with historical controls, demonstrating that HCC incidence is reduced with entecavir therapy (HEPATOLOGY 2013.)